Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037551 | 0.78 | POLB (0.38) | POLBALDH1A1LMNAHTTHPGD | |
| SCHEMBL10037553 | 0.78 | SLC1A2 (0.38) | ALDH1A1LMNAHTTHPGDKDM4E | |
| SCHEMBL9064507 | 0.76 | CSNK2A2 (0.46) | POLBALDH1A1LMNAHTTHPGD | |
| SCHEMBL10050025 | 0.70 | ALDH1A1 (0.33) | POLBALDH1A1LMNAHTTKDM4E | |
| SCHEMBL4404816 | 0.69 | XPO1 (0.33) | — | |
| SCHEMBL15394245 | 0.68 | JUN (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL14868141 | 0.68 | JUN (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL10037952 | 0.68 | POLB (0.33) | POLBMAPT | |
| SCHEMBL16266924 | 0.67 | MEN1 (0.38) | POLBALDH1A1LMNAHPGDMAPT | |
| SCHEMBL8440537 | 0.67 | MEN1 (0.38) | POLBALDH1A1LMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124791-B2 | Active energy ray curable liquid composition and liquid cartridge | CANON KABUSHIKI KAISHA (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | CANON KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | C9, MLX, CHRM1 | POLB 207/4885ALDH1A1 3555/4885LMNA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.